Passage Bio PASG shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $29 price target.
The firm said the company’s gene therapy platform and UPenn collaboration will create significant value for investors with multiple inflection events approaching in the next 6-12 months.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders.
At the time of publication, shares of Passage Bio were trading 13.2% higher at $14.99. The stock has a 52-week low of $12.10 and a 52-week high of $30.87.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.